Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04829916
Other study ID # 20-ROS-04
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 16, 2021
Est. completion date July 15, 2021

Study information

Verified date April 2024
Source Guard Therapeutics AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.


Description:

This is a study with two parallel treatment groups where subjects are randomized to receive RMC-035 or a matching placebo in a double-blind fashion. The study will comprise of a screening visit, followed by CABG and/or valve replacement on Day 1, double-blind treatment period and a follow-up period up to Day 30.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date July 15, 2021
Est. primary completion date July 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Key Inclusion Criteria: - Female and male subjects with an age =18 years - Subject is scheduled for non-emergent (elective) CABG and/or valve surgery (single or multiple valves) with use of cardiopulmonary bypass (CPB) - Subject has at least ONE of the following risk factors for AKI at screening: - History of LVEF <35% for at least 3 months prior to screening assessed by either echocardiography, cardiac MRI or nuclear scan. - History of previous open chest cavity cardiac surgery with or without CPB - Confirmed diagnosis of type 2 diabetes (T2DM) at least 3 months prior to screening AND ongoing treatment with an approved anti-diabetic drug - Age =70 years - Documented history of heart failure NYHA class II or higher for at least 3 months or longer at screening - Documented history of previous AKI before date of screening independent of the etiology of AKI - Documented history of anemia with hemoglobin = 11 g/dL (=6.8 mmol/L) for at least 3 months prior to screening - Documented history of albuminuria, defined as UACR >30 mg/g or > 30 mg/24 hour in a 24-hour urine collection. - eGFR is = 60 mL/min/1.73 m2 using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation Key Exclusion Criteria: - Estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m2 using the Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI) equation at screening or at baseline - Subject has surgery scheduled to be performed without CPB ("off-pump") - Subject has surgery scheduled for aortic dissection - Subject is scheduled for CABG and/or valve surgery combined with additional non-emergent cardiac surgeries, e.g. for atrial fibrillation ablation - Subject is scheduled to undergo trans catheter aortic valve implantation (TAVI) or trans catheter aortic valve replacement (TAVR), or single vessel off-pump surgeries or left ventricular device (LVAD) implantation - Subject has a requirement for any of the following within one week prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, other forms of mechanical circulatory support (MCS) (Note: The prophylactic insertion of an IABP preoperatively for reasons not related to existing LV pump function is not exclusionary)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RMC-035
Multiple dosing during 48 hours following cardiac surgery
Placebo
Multiple dosing during 48 hours following cardiac surgery

Locations

Country Name City State
Germany Münster University Hospital Münster

Sponsors (1)

Lead Sponsor Collaborator
Guard Therapeutics AB

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Adverse Events (AEs) number (%) of subjects with at least one AE
number (%) of subjects with at least one SAE
number (%) of subjects with at least one Treatment-Emergent AE (TEAE)
number (%) of subjects with at least one serious TEAE
number (%) of subjects with at least one non-serious TEAE
number (%) of subjects with at least one TEAE of special interest
number (%) of subjects with at least one TEAEs reported as related (possible/probable) to IMP
number (%) of subjects with at least one TEAEs leading to withdrawal of IMP
Baseline through day 30
Primary Severity of AEs - Number of TEAEs per category (mild, moderate, severe life-threatening, death) Within 4 days from first dose of IMP
Secondary Maximum Observed Concentration (Cmax) Analysis of RMC-035 concentration in plasma (AUC + t1/2) after fourth infusion. Blood samples taken from pre-dose and up to two hours after start of Dose 5
Secondary Area Under the Curve (AUC) 0-24h Analysis of RMC-035 concentrations in plasma following the fourth infusion. Blood samples taken from pre-dose and up to two hours after start of Dose 5
Secondary Elimination Half-life (T1/2) Analysis of RMC-035 concentration in plasma following the fourth infusion Blood samples taken from pre-dose and up to two hours after start of Dose 5
See also
  Status Clinical Trial Phase
Completed NCT03941483 - Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery Phase 2
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT05068167 - Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery
Completed NCT04165369 - Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury
Terminated NCT02620761 - Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Phase 2/Phase 3
Recruiting NCT05264285 - Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
Recruiting NCT05399537 - Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT Phase 3